Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE HCT vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Hypertension: treatment of hypertension to lower blood pressure (FDA-approved)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Valsartan: 6 hours (terminal). Amlodipine: 30-50 hours (terminal), permits once-daily dosing. Hydrochlorothiazide: 6-15 hours (terminal).
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Amlodipine is extensively metabolized in the liver via CYP3A4; valsartan is minimally metabolized (about 20%) via CYP2C9; hydrochlorothiazide is not metabolized and is excreted unchanged.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Valsartan: 13% excreted unchanged in urine, 83% in feces via biliary secretion. Amlodipine: 10% excreted unchanged in urine, 60% as metabolites in urine, 20-25% in feces. Hydrochlorothiazide: ≥95% excreted unchanged in urine.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Valsartan: 94-97% (primarily albumin). Amlodipine: ~93% (albumin). Hydrochlorothiazide: 40-68% (albumin).
~10-20% bound to plasma proteins (primarily albumin).
Valsartan: 17 L (0.24 L/kg); indicates limited extravascular distribution. Amlodipine: 21 L/kg; extensive tissue distribution. Hydrochlorothiazide: 3-15 L (0.05-0.2 L/kg); distributes into extracellular fluid.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: Valsartan 25% (wide range 10-35%), amlodipine 64-90%, hydrochlorothiazide 65-75%.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
Contraindicated in anuria. For GFR 30-60 m L/min: no dose adjustment needed, but monitor serum potassium and creatinine. For GFR <30 m L/min: not recommended due to limited data.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh Class A: no adjustment; Class B: maximum dose 5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide; Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Initiate at the lowest available dose (5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide) and titrate slowly; monitor renal function, electrolytes, and blood pressure due to increased risk of hypotension and electrolyte imbalance.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
WARNING: FETAL TOXICITY. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
None
Fetal toxicity: avoid use in pregnancy; discontinue if pregnancy occurs.,Hypotension: symptomatic hypotension may occur, especially in volume-depleted patients.,Electrolyte and metabolic effects: hydrochlorothiazide may cause hypokalemia, hyponatremia, hypercalcemia, hypomagnesemia, and hyperglycemia.,Renal function deterioration: monitor renal function; may cause acute renal failure.,Hepatic impairment: use caution in patients with severe hepatic impairment.,Angioedema: reported with valsartan; monitor for swelling of face, lips, throat.,Avoid concomitant use with aliskiren in patients with diabetes or renal impairment.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to any component.,Anuria (due to hydrochlorothiazide).,Concomitant use with aliskiren in patients with diabetes mellitus.,Severe renal impairment (e GFR <30 m L/min/1.73 m²).,Pregnancy (second and third trimesters).,Hereditary fructose intolerance (due to sorbitol excipient in some formulations).
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and salt substitutes with potassium unless instructed otherwise. Grapefruit juice may increase amlodipine levels; limit consumption. Alcohol may enhance hypotensive effects. Maintain adequate fluid intake to prevent dehydration.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossification defects, and fetal death if exposed during first trimester. However, major teratogenic risk is primarily second and third trimester. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Second and third trimester: Valsartan exposure is associated with oligohydramnios, fetal renal failure, skull hypoplasia, anuria, and death. HCTZ can cause fetal electrolyte imbalances, jaundice, and thrombocytopenia. Avoid use in pregnancy, especially second and third trimesters.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Valsartan: Not known if excreted in human milk; due to potential for adverse effects on infant kidney function, caution advised. Hydrochlorothiazide: Excreted in breast milk in small amounts; M/P ratio approximately 0.6. May suppress lactation. Use only if clearly needed, monitoring infant for electrolyte disturbances and dehydration.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Not recommended for use in pregnancy. If unavoidable, use lowest effective dose; however, pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may require dose adjustments, but safety data insufficient. Generally, avoid use.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Exforge HCT is a triple combination of amlodipine, valsartan, and hydrochlorothiazide. It is indicated for hypertension not adequately controlled on dual therapy. Monitor serum potassium, especially in patients with renal impairment or on NSAIDs. Avoid use in pregnancy due to direct renin-angiotensin system effects. Titrate doses based on blood pressure response. Common side effects include peripheral edema (amlodipine), dizziness, and electrolyte disturbances (HCTZ).
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed, usually once daily with or without food.,Do not stop taking this medication without consulting your doctor.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or low blood pressure (dizziness, fainting).,Avoid potassium supplements or salt substitutes containing potassium unless advised by your doctor.,Limit alcohol intake as it may increase blood pressure or cause dizziness.,If pregnant or planning pregnancy, inform your doctor immediately as this drug can harm an unborn baby.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Stay hydrated to prevent dehydration from hydrochlorothiazide, especially if you sweat heavily or have diarrhea/vomiting.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE HCT vs ALDOMET, answered by our medical review team.
EXFORGE HCT is a Antihypertensive that works by EXFORGE HCT is a combination of amlodipine (a dihydropyridine calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide increases excretion of sodium and water by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE HCT and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE HCT is: One tablet orally once daily. Initial dose based on previous antihypertensive therapy; maximum dose is one tablet of 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide per day.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE HCT and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE HCT is classified as Category C. First trimester: Drugs acting on renin-angiotensin system (ARB/ACEi component: valsartan) associated with increased risk of fetal renal dysfunction, oligohydramnios, skull ossifica. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.